Blood Test May Detect Early Alzheimer’s: Scientists Edge Closer to Early Detection

Researchers at the University of California, San Francisco (UCSF) are developing a blood test that may identify early cognitive decline associated with Alzheimer’s disease, according to reports published June 6, 2026. This development is part of a broader scientific effort to move toward earlier detection through blood-based biomarkers, cardiovascular screening, and improved imaging accuracy.

How is UCSF using blood tests for early detection?

A first-of-its-kind study from UCSF indicates that a blood test may be capable of catching early cognitive trouble, according to SFGATE. The research suggests that blood-based screening could provide a less invasive way to identify the onset of Alzheimer’s symptoms before they become severe.

The Daily Star reports that these findings bring scientists closer to a viable blood test for forgetfulness, potentially reducing the reliance on more invasive or expensive diagnostic procedures for early-stage detection.

What role do cardiovascular biomarkers play in screening?

Beyond direct blood tests for cognitive markers, research published in Cureus argues for the use of cardiovascular biomarkers as a primary care gateway to early Alzheimer’s detection. The publication advocates for an integrated screening approach that monitors heart-related health markers to identify patients who may be at higher risk for cognitive decline.

This approach differs from the UCSF study by focusing on the intersection of cardiovascular health and neurological decline, suggesting that primary care physicians could use existing heart-health data to trigger earlier Alzheimer’s screenings.

How does new imaging improve Alzheimer’s accuracy?

While blood tests and biomarkers offer screening potential, new imaging technology is being developed to confirm diagnoses with higher precision. Gulf Coast News and Weather reports that researchers have developed a new imaging test designed to detect Alzheimer’s with greater accuracy than previous methods.

This imaging advancement complements the blood-test research by providing a more precise visual confirmation of the disease’s progression in the brain, addressing the need for high-accuracy diagnostics following an initial positive screen.

What other assessments are being developed?

In addition to blood and imaging tests, Healthcare Today reports the development of a new assessment intended for the earlier detection of Alzheimer’s. While the specific nature of this assessment was not detailed, it aligns with the current trend of diversifying the tools available to clinicians for early intervention.

The current landscape of Alzheimer’s research shows a three-pronged shift in detection strategies: accessible blood-based screenings, integrated primary care monitoring via cardiovascular markers, and high-accuracy imaging for confirmation.